CLNN - Clene Inc.
Clene Inc. Logo

CLNN - Clene Inc.

https://clene.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of new clean-surface nanotechnology (CSN) therapies. The company is headquartered in Salt Lake City, Utah.

52W High
$6.83
52W Low
$2.28
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.57
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-1.13
EV/Revenue (<3 favorable)
258.06
P/S (TTM) (<3 favorable)
210.64
P/B (<3 favorable)
7.83
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
31.08%
Institutions (25–75% balanced)
16.55%
Shares Outstanding
9,990,600
Float
7,152,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
286,000
Gross Profit (TTM)
230,000
EPS (TTM)
-3.78
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-217.19%
ROE (TTM) (>15% strong)
-17.38%
EPS YoY (Quarterly) (>10% good)
0.61
Revenue YoY (Quarterly) (>8% good)
-0.70
Momentum
Bearish momentum
Value
0.6461
Previous
0.7271
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025